Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida. The company is developing medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019.
| Company type | Public |
|---|---|
Traded as | Nasdaq: CPRX Russell 2000 Component S&P 600 Component |
| Industry | Biotechnology |
| Founder | Patrick J. McEnany |
| Headquarters | Coral Gables, Florida, U.S. |
Key people | Patrick J. McEnany (chairman, president and CEO) |
| Products | FIRDAPSE® (amifampridine) Tablets 10 mg (commercialized 2019) |
| US$ 52.38 million (2022) | |
| Total assets | US$ 267.31 million (2022) |
| Total equity | US$ 237.79 million (2022) |
Number of employees | 76 as of March 14, 2022 |
| Website | www.catalystpharma.com |
| Footnotes / references | |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.